Metocard

Metoprolol Tartrate, the active ingredient in Metocard, is a beta‑adrenergic blocking agent presented as an intravenous solution for intravenous administration. It is used to manage hypertension, angina pectoris, acute myocardial infarction and various cardiac arrhythmias in adult patients.

GNH USA supplies Metocard as a licensed, Good Distribution Practice‑compliant pharmaceutical product, providing reliable access to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through its international supply network across multiple regions. All shipments meet EU regulatory standards and are tracked for quality assurance.

Metocard (metoprolol tartrate) is a selective β1‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers blood pressure by reducing heart rate and cardiac output. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Acute myocardial infarction: improves survival by limiting heart workload during the event. - Cardiac arrhythmias: stabilises abnormal heart rhythms by slowing conduction through the AV node.

Metocard may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headed sensation, especially on standing. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Headache: mild to moderate pain in the head. - Gastrointestinal upset: nausea, abdominal discomfort.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Acute heart failure: sudden worsening of cardiac function. - Allergic reactions: rash, swelling, or anaphylaxis.

When using Metocard, clinicians should consider several safety measures to minimise risk.

- Renal impairment: adjust dose and monitor kidney function. - Asthma or COPD: use with caution as β‑blockade may worsen bronchospasm. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Blood pressure and heart rate: monitor regularly during therapy. - Diabetes: be aware that hypoglycemia signs may be masked. - Store at room temperature: keep in original container, protect from light and moisture.

Metocard can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Calcium channel blockers (verapamil, diltiazem): may cause excessive bradycardia. - Clonidine: abrupt withdrawal can lead to rebound hypertension. - Antidiabetic agents: may mask symptoms of low blood sugar.

Moderate Interactions (Monitor Closely): - ACE inhibitors: additive blood‑pressure lowering effect. - Diuretics: may cause electrolyte disturbances. - NSAIDs: can reduce antihypertensive efficacy.